Evidence map›Paper›PMID 41146908›Full record

ArticleCommunications materials2025

Anionic lipids direct efficient microfluidic encapsulation of stable and functionally active proteins in lipid nanoparticles.

Suresh Ambati, Yeqi Li, Matthew K Whittaker, Eileen J Kennedy, Wided N Missaoui, Xiaorong Lin, Zachary A Lewis, Richard B Meagher

Abstract read
In one paragraph

Article in Communications materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Formulation of Peptide-Based Nanoparticles Using a Microfluidic Device.Journal of peptide science : an official publication of the European Peptide Society · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Altering the ligand specificity of DectiSomes.The Journal of biological chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Suresh AmbatiDavison Life Sciences Bld., Green Street, Department of Genetics, University of Georgia, Athens, GA 30602 USA.
Yeqi LiBuilding C, 136 Cedar Street, Department of Microbiology, University of Georgia, Athens, GA 30602 USA.
Matthew K WhittakerPharmacy South, Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602 USA.ORCID 0000-0002-1846-6402
Eileen J KennedyPharmacy South, Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602 USA.ORCID 0000-0001-5610-1677
Wided N MissaouiPharmacy South, Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602 USA.
Xiaorong LinBuilding C, 136 Cedar Street, Department of Microbiology, University of Georgia, Athens, GA 30602 USA.ORCID 0000-0002-3390-8387
Zachary A LewisDavison Life Sciences Bld., Green Street, Department of Microbiology, University of Georgia, Athens, GA 30602 USA.ORCID 0000-0002-1735-8266
Richard B MeagherDavison Life Sciences Bld., Green Street, Department of Genetics, University of Georgia, Athens, GA 30602 USA.

Funding

Targeted Pan-Antifungal LiposomesR01AI162989 · NIAID · UNIVERSITY OF GEORGIA · PI Zachary Lewis, Richard Brian Meagher · 2022 to 2026
$2.6M
Targeting WASF3 to suppress metastasisR01GM134168 · NIGMS · UNIVERSITY OF GEORGIA · PI KENNEDY, EILEEN J · 2019 to 2022
$1.2M
JEOL 2100PLUS(CR)S10OD034282 · OD · UNIVERSITY OF GEORGIA · PI SALGUERO, TINA · 2023 to 2023
$1.2M
Antifungal Liposomes Targeted to Cell Wall MannansR21AI148890 · NIAID · UNIVERSITY OF GEORGIA · PI MEAGHER, RICHARD BRIAN · 2020 to 2021
$415k
Targeted delivery of antifungal drug loaded liposomes to control mucormycosisR21AI171787 · NIAID · UNIVERSITY OF GEORGIA · PI MEAGHER, RICHARD BRIAN · 2022 to 2023
$415k
Targeted pan-antibacterial liposomes to control pathogenic mycobacteriaR21AI173492 · NIAID · UNIVERSITY OF GEORGIA · PI MEAGHER, RICHARD BRIAN · 2023 to 2024
$415k
Antifungal ImunoliposomesR21AI144498 · NIAID · UNIVERSITY OF GEORGIA · PI MEAGHER, RICHARD BRIAN · 2019 to 2020
$415k
NIAID NIH HHS R01 AI162989NIAID NIH HHS R21 AI144498NIAID NIH HHS R21 AI148890NIAID NIH HHS R21 AI171787NIAID NIH HHS R21 AI173492NIGMS NIH HHS R01 GM134168NIH HHS S10 OD034282
6 · The paper itself

Abstract

Because proteins do not efficiently pass through the plasma membrane, protein therapeutics are limited to target ligands located at the cell surface or in serum. Lipid nanoparticles can facilitate delivery of polar molecules across a membrane. We hypothesized that because most proteins are amphoteric ionizable polycations, proteins would associate with anionic lipids, enabling microfluidic chip assembly of stable EP-LNPs (Encapsulated Proteins in Lipid NanoParticles). Here, by employing anionic lipids we were able to efficiently load proteins into EP-LNPs at protein:lipid w:w ratios of 1:20. Several proteins with diverse molecular weights and isoelectric points were encapsulated at efficiencies of 70 75%-90% and remained packaged for several months. Proteins packaged in EP-LNPs efficiently entered mammalian cells and fungal cells with cell walls. The proteins delivered intracellularly were functional. EP-LNPs technology should improve cellular delivery of medicinal antibodies, enzymes, peptide antimetabolites, and dominant negative proteins, opening new fields of protein therapeutics.

Indexed as

Biological techniquesProtein delivery

Identifiers

PMID41146908
PMCPMC12553553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.